<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092648</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2016-187</org_study_id>
    <nct_id>NCT03092648</nct_id>
  </id_info>
  <brief_title>Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regend Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a kind of chronic bronchitis or emphysema
      with characteristics of long-term poor airflow, resulting in chronic pulmonary heart disease,
      chronic respiratory failure or even death. Anatomically, the pulmonary bronchus structures in
      COPD patients are damaged and cannot be repaired by recent clinical treatment so far. This
      study intends to carry out an open, single-armed, phase I/II clinical trial to investigate
      whether bronchial basal cells can regenerate damaged lung tissue. During the treatment,
      bronchial basal cells will be isolated from patients' own bronchi and expanded in vitro.
      After careful characterization, cultured cells will be transplanted autologously into the
      lesion by fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored
      by measuring the key clinical indicators.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open, non-random, concurrent control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>1-6 months</time_frame>
    <description>One of the indicators for pulmonary function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>1-6 months</time_frame>
    <description>One of the indicators for pulmonary function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC, MMF, MVV and DLCO</measure>
    <time_frame>1-6 months</time_frame>
    <description>Other indicators for the pulmonary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test (6MWT)</measure>
    <time_frame>1-6 months</time_frame>
    <description>Indicator to evaluate the exercise function of patients with moderate or severe pulmonary heart diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMRC</measure>
    <time_frame>1-6 months</time_frame>
    <description>Indicator to evaluate the level of dyspnea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ</measure>
    <time_frame>1-6 months</time_frame>
    <description>A questionnaire to assess life quality affected by the respiratory problems</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Bronchial basal cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bronchial basal cell</intervention_name>
    <description>autologous bronchial basal cell transplantation</description>
    <arm_group_label>Bronchial basal cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 40 to 75;

          -  Diagnosed with COPD according the guideline (a. with symptoms of productive cough,
             sputum production or shortness of breath; b. with poor airflow as indicated by
             FEV1&lt;70% predicted value and FEV1/FVC &lt; 0.7 in pulmonary function test; c. with
             exclusion of other pulmonary disease by CT or blood examination.);

          -  Clinically stable for more than 4 weeks;

          -  Tolerant to bronchofiberscope;

          -  Written informed consent signed.

        Exclusion Criteria:

          -  Pregnant or lactating women;

          -  Patients positive for syphilis, HIV;

          -  Patients with malignant tumor;

          -  Patients with serious significant pulmonary infection and need anti-infection
             treatment;

          -  Patients with serious heart disease(NYHA class Ⅲ-Ⅳ);

          -  Patients with a history of abusing alcohol and illicit drug;

          -  Patients participated in other clinical trials in the past 3 months;

          -  Patients assessed as inappropriate to participate in this clinical trial by
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zuo, Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Regend Therapeutics Co.Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guodong Hu, M.D.</last_name>
    <email>huguodong123123@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Zuo, Ph. D.</last_name>
    <email>zuow@regend.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guodong Hu, M. D.</last_name>
      <email>huguodong123123@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Zuo, Ph. D.</last_name>
      <email>zuow@regend.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Guodong HU</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

